The use of statin therapy in adults 65 years old or older may not be associated with incident dementia, mild cognitive impairment (MCI) or decline in individual cognition domains, according to a study published June 21 in the Journal of the American College of Cardiology. Zhen Zhou, PhD, et al., analyzed data from the ASPREE trial – a large prospective, randomized placebo-controlled trial of…

“In patients who had discontinued statin therapy because of side effects, 90% of the symptom burden elicited by a statin challenge was also elicited by placebo,” said researchers presenting findings from the SAMSON trial Nov. 15 during AHA 2020. The trial, which was also published in the New England Journal of Medicine, also found that half of trial participants…

An individual’s risk of future cardiovascular events may depend both on cumulative exposure to LDL-C concentration and, independently, on the time course of LDL-C accumulation, according to a study published Sept. 21 in the Journal of the American College of Cardiology. Michael J. Domanski, MD, FACC, and Valentin Fuster, MD, PhD, MACC, et al., developed a risk…

LDL-C levels after coronary revascularization with PCI was strongly associated with the subsequent incidence of major adverse cardiovascular events (MACE), according to a study published Sept. 14 in the Journal of the American College Cardiology. Maneesh Sud, MD, et al., evaluated LDL-C testing and levels after PCI in 47,884 patients who received their first…

Statins appear to prevent physical disability and cardiovascular disease in healthy community-dwelling adults ≥70 years old, but do not prolong disability-free survival or avoid the risk of death or dementia, according to a study published June 29 in the Journal of the American College of Cardiology. Using data from the double-blind, randomized ASPREE trial,…